WAM
GLMD icon

Wealthspire Advisors (Maryland)’s Galmed Pharmaceuticals GLMD Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-75
Closed -$65K – 504
2019
Q3 		$65K Buy
+75
New +$75.2K ﹤0.01% 457

Other funds holding GLMD

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s GLMD Position: Q4 2019 in Review

Wealthspire Advisors (Maryland) sold out of Galmed Pharmaceuticals (GLMD) in Q4 2019, closing a stake of 75 shares — an estimated $65K sold.

Wealthspire Advisors (Maryland) first reported a position in GLMD in Q3 2019 and held it in 1 quarter. The position peaked at $65K in Q3 2019. 31 funds tracked by Wall St. Rank hold GLMD as of Q4 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Galmed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 75 Galmed Pharmaceuticals shares in Q4 2019, an estimated $65K.
  • Wealthspire Advisors (Maryland) first reported a position in Galmed Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Wealthspire Advisors (Maryland)'s Galmed Pharmaceuticals position peaked at $65K in Q3 2019.
  • 31 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q4 2019, filed 14 Feb 2020.